This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women’s health.

The Genzyme Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Analysis and opinion on monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, private placement, IPO, and secondary offering deals.

The Johnson & Johnson Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies

The Servier Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This brief offers an analysis of PLM technology and the six key features that will make PLM successful in the pharmaceutical industry.

The AstraZeneca Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Barr Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

CurrentPartnering’s Practical Guide to Finding Partners in Biopharma provides a comprehensive overview of all the steps required to identify and secure partnering either for an in-licensing or out-licensing activity

The Novo Nordisk Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This report is a ’how to’ for drafting licensing and partnering agreements, aimed at individuals in marketing, business development and technology transfer who need a backgrounder in the subject to support discussions with lawyers and partn

As the shift towards translational research continues, the pharmaceutical industry is accelerating its spending on business intelligence (BI). This Datamonitor report forecasts and analyzes the IT opportunity for vendors serving the Big Pharma and Biot

The UCB Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Pfizer Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Eisai Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Analysis of every Big Pharma-led M&A permutation within the PharmaVitae Rx pharma universe from a sales growth rate perspective, with relation to each target’s market capitalization and, for the optimal combinations, strategic implications.

The Alcon Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Menarini Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Boehringer Ingelheim Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This report provides companies with the clinical data to further scientific understanding of their drugs. IIT findings help to expand on- and off-label usage, reach new patient populations, generate data for publication and solidify relationships with

The Bristol-Myers Squibb Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies

The Procter & Gamble Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The average value of pharma-biotech deals will almost treble by 2015 as pharma companies focus on gaining exclusive access to high potential technologies via large equity investments...

The Eli Lilly Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Forest Labs Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Stada Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This brief offers an analysis of strategic approaches to implementing PLM in the pharmaceutical industry

The Astellas Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies